“一带一路”背景下中国医药产品贸易的竞争力分析【摘要】共同发展和共同繁荣是中国和“一带一路”沿线国家之间需要完成的共同目标，中国和“一带一路”沿线国家之间的医药产品贸易有助于这个目标的实现 。 为 了 研 究 中 国 在 医 药 产 品 方 面 的 国 际 竞 争 力 ， 本 文 使 用 Revealed Comparative Advantage（显示性比较优势指数）以及 Trade Competitiveness（竞争力指数）进行数据分析，从数据分析出的结果可以知道，中国的医药产品贸易无论是比较优势方面还是竞争力方面都与“一带一路”某些成员国的医药产品贸易有着一段差距。通过研读众多资料发现，无论是中国的医药产业结构，或是医药企业的自主研发能力，还是医药市场竞争环境都存在着不足，若能够对这些不足加以改进，或许能使中国医药产品贸易的国际竞争力再上一层，从而得到真正的提升，使得中国和“一带一路”沿线国家之间的医药产品贸易合作更加长久顺利。【关键字】医药产品贸易；显示性比较优势指数；“一带一路”战略注：本论文（设计）题目来源于教师的国家级（或省部级、厅级、市级、校级、企业）科研项目，项目编号为： 。The Research on International Competitiveness of Trade in Pharmaceutical products of China Under "OBOR"[Abstract]Common development and common prosperity are the common goals to be completed between China and the countries along the “Belt and Road”. The trade of pharmaceutical products between China and the countries along the “Belt and Road” will help achieve this goal. In order to study China’s international competitiveness in pharmaceutical products , this thesis uses the Revealed Comparative Advantage Index and Trade Competitiveness for date analysis, and the results from the date analysis can be known, China's trade in pharmaceutical products has a gap between the trade in medicine of certain member countries of the “Belt and Road” in terms of comparative advantage or competitiveness. Through studying many materials, it is found that whether it is China's pharmaceutical industry...
